Resistenza agli antibiotici in particolare da batteri Gram-negativi ha quasi creato una situazione di crisi. Il nuovo antibiotico Zosurabalpin (RG6006) promette bene. Negli studi preclinici è stato riscontrato che è efficace contro i batteri Gram-negativi CRAB resistenti ai farmaci.
Antimicrobial resistance (AMR), driven mainly by the misuse and overuse of antimicrobials, is one of top public health risk.
Infections by Gram-negative bacteria are particularly concerning. It is not easy for most of antibiotici to cross both inner and outer membranes present in this category of bacteria to enter the bacterial cells to show bactericidal actions. Also, Gram-negative bacteria have accumulated disproportionately high degree of antibiotico resistenza.
Acinetobacter baumannii is a Gram-negative bacterium. Infection by one of its strains called ‘carbapenem-resistant Acinetobacter baumannii’ (CRAB) is hard to treat using available antibiotici. There is an urgent need for an effective antibiotico against CARB as mortality rate is high (about 40%-60%) which attributed largely to lack of an effective antibiotico. A progress towards this goal has been reported.
Scientists have identified a novel class of antibiotici namely, tethered macrocyclic peptides (MCPs) which are active against the Gram –ve bacteria A. baumannii including CARB by blocking transport of bacterial lipopolysaccharide from the inner membrane to the outer membrane.
Zosurabalpina (RG6006) offre antibiotico candidate belonging to ‘tethered macrocyclic peptides (MCPs)’ class. In pre-clinico trials involving in vitro studies and in vivo studies on animal models, Zosurabalpin has been found to be effective against drug-resistant isolates of ‘carbapenem-resistant Acinetobacter baumannii’ (CRAB) from different regions. It successfully overcame antibiotico-resistance mechanism of CARB suggesting Zosurabalpin ha potenziale.
Hence, human clinico trials have been initiated to check for safety and efficacy Zosurabalpin nel trattamento delle infezioni invasive causate da CRAB.
***
Riferimenti:
- Zampaloni, C., Mattei, P., Bleicher, K. et al. A novel antibiotico class targeting the lipopolysaccharide transporter. Nature (2024). https://doi.org/10.1038/s41586-023-06873-0
- Hawser S., et al 2023. Activity of the Novel Antibiotic Zosurabalpin (RG6006) against Info su Acinetobacter Isolates from China, Open Forum Infectious Diseases, Volume 10, Issue Supplement_2, December 2023, ofad500.1754, https://doi.org/10.1093/ofid/ofad500.1754
***
